$5.29 Billion in Sales Expected for Bristol-Myers Squibb Company (BMY) This Quarter
Equities research analysts predict that Bristol-Myers Squibb Company (NYSE:BMY) will announce sales of $5.29 billion for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bristol-Myers Squibb’s earnings. The lowest sales estimate is $5.20 billion and the highest is $5.43 billion. Bristol-Myers Squibb posted sales of $5.24 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 1%. The company is scheduled to report its next quarterly earnings report on Thursday, January 25th.
On average, analysts expect that Bristol-Myers Squibb will report full-year sales of $5.29 billion for the current fiscal year, with estimates ranging from $20.44 billion to $20.77 billion. For the next financial year, analysts forecast that the business will post sales of $21.25 billion per share, with estimates ranging from $20.82 billion to $21.78 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the firm earned $0.77 earnings per share. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis.
BMY has been the subject of a number of research reports. Deutsche Bank AG set a $55.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, July 17th. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target for the company. in a research report on Tuesday, July 25th. BMO Capital Markets reissued an “underperform” rating and issued a $47.00 price target (down from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Piper Jaffray Companies set a $60.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, July 27th. Finally, Leerink Swann reduced their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $64.93.
Shares of Bristol-Myers Squibb (BMY) traded down $1.13 on Monday, reaching $60.86. 5,592,700 shares of the company were exchanged, compared to its average volume of 8,740,103. Bristol-Myers Squibb has a 52-week low of $46.01 and a 52-week high of $66.10. The stock has a market capitalization of $99,609.57, a PE ratio of 20.56, a PEG ratio of 2.40 and a beta of 1.18. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.56%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.23% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. Atlantic Trust LLC acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC grew its position in shares of Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. grew its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its position in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 504 shares during the last quarter. Institutional investors and hedge funds own 69.51% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.